LA JOLLA, Calif. – Synthetic Genomics, Inc. and ExxonMobil (NYSE: XOM) announced today that they have extended their agreement to conduct joint research into advanced algae biofuels after making significant progress in understanding algae genetics, growth characteristics and increasing oil production. ExxonMobil and Synthetic Genomics have been jointly researching and developing oil from algae for […]
SAN DIEGO, Jan. 9, 2017 /PRNewswire/ — Synthetic Genomics Inc. announced today that its subsidiary, SGI-DNA, has launched Vmax™ Express, a highly advanced bacterial host organism designed for significant improvement in recombinant protein expression. Compatible with standard plasmids, antibiotics and growth media used in other bacterial protein expression systems, Vmax™ Express generates larger amounts of soluble […]
SAN DIEGO, Jan. 5, 2017 – Synthetic Genomics, Inc., announced today that it has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to apply Synthetic Genomics’ proprietary replicon RNA technology toward the design and development of novel RNA-based medicines for specific […]
LA JOLLA, Calif. – November 22, 2016 – Synthetic Genomics, Inc., announced today that Oliver Fetzer, Ph.D., chief executive officer, will present at two upcoming conferences.
LA JOLLA, Calif. – November 9, 2016 – Synthetic Genomics, Inc., announced today that it has appointed industry veterans Tina Nova, Ph.D., and William McKee to its board of directors.
Optimized system has potential to replace the workhorse E. coli by increasing speed and efficiency of protein production and cloning LA JOLLA, CA – August 29, 2016 – Researchers from Synthetic Genomics, Inc. (SGI) announced today the development and extensive engineering of Vibrio natriegens into a next-generation biotechnology host organism Vmax™. Looking to accelerate the […]
(LA JOLLA, CA)—August 4, 2016—Researchers from the J. Craig Venter Institute (JCVI) and Synthetic Genomics, Inc. (SGI) have published research describing a method for engineering Mycoplasma mycoides 16S ribosomal RNA (rRNA) using a one-step process that combines CRISPR/Cas9 gene editing system with yeast recombination machinery. The rRNAs are some of the most conserved genes in […]
LA JOLLA, CA – June 6, 2016 – Synthetic Genomics, Inc. (SGI) announced today that Oliver Fetzer, Ph.D., MBA, Chief Executive Officer of Synthetic Genomics, Inc., will provide a corporate overview and presentation at the Jefferies 2016 Healthcare Conference on Friday, June 10, 2016 at 8:30am ET (5:30am PT) in New York, NY. About Synthetic Genomics […]
La Jolla, CA, May 3, 2016—Synthetic Genomics, Inc. (SGI), a leader in the field of synthetic biology, announced today that Anthony Artuso has joined its executive team as Chief Business Officer. Anthony is an accomplished executive and entrepreneur with over 20 years of broad domestic and international experience in biotech, clean energy, finance, public policy, […]
(LA JOLLA, CA)—March 24, 2016—Researchers from Synthetic Genomics Inc. (SGI) and the J. Craig Venter Institute (JCVI) announced today the design and construction of the first minimal synthetic bacterial cell, JCVI-syn3.0. Using the first synthetic cell, Mycoplasma mycoides JCVI-syn1.0 (created by this same team in 2010), JCVI-syn3.0 was developed through a design, build, and test […]